Low-Dose IL-2 Therapy Shows Promise in Sjögren’s Syndrome Clinical Trial

A randomized clinical trial has found that low-dose interleukin-2 (IL-2) therapy may improve symptoms and immune function in people with primary Sjögren’s syndrome, a chronic autoimmune disease that affects moisture-producing glands. In the study, patients who received IL-2 showed measurable improvements in disease activity scores, including reductions in dryness, fatigue, and joint discomfort.

IL-2 is a naturally occurring immune molecule that plays a role in regulating immune responses. At low doses, it appears to selectively expand regulatory T cells, which help control autoimmune activity. This is important in Sjögren’s syndrome, where the immune system mistakenly attacks the body’s own glands.

Unlike traditional treatments that broadly suppress the immune system, IL-2 may help restore immune balance. This approach could potentially reduce side effects such as increased infection risk. In the study, the therapy was generally well tolerated, and no serious adverse events were reported.

Although the study was relatively small, the findings are encouraging and support further research. Larger clinical trials will be needed to confirm long-term safety and effectiveness. For patients, this research suggests that future treatments may focus more on correcting immune dysfunction rather than simply managing symptoms.

This represents a meaningful shift in how autoimmune diseases like Sjögren’s syndrome may be treated in the future.